SMA Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

SMA Capital’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.6K	Buy	169 +89	+111%	+$5.69K	﹤0.01%	104
2026 Q1	$5.61K	Buy	+80	New	+$5.59K	﹤0.01%	86

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SMA Capital's TARS Position: Q2 2026 in Review

SMA Capital increased its Tarsus Pharmaceuticals (TARS) stake by 111% in Q2 2026, buying an estimated $5.69K and bringing the position to 169 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #104.

SMA Capital first reported a position in TARS in Q1 2026 and has held it in 2 quarters since. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

SMA Capital held 169 shares of Tarsus Pharmaceuticals worth $10.6K as of Q2 2026.
SMA Capital bought 89 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $5.69K.
Tarsus Pharmaceuticals made up ﹤0.01% of SMA Capital's portfolio in Q2 2026, its #104 holding.
SMA Capital first reported a position in Tarsus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.